Targeting Kinase Inhibitor Induced DNA-Damage Response in Ph-Like ALL |
Temple University / Christian Hurtz, PhD |
'A' Award Grants |
2022 |
Pennsylvania |
BH3 profiling to define therapy resistance classes in neuroblastoma.
|
Children’s Hospital of Philadelphia / Michael Hogarty |
Innovation Grants |
2009 |
Pennsylvania |
Beyond Febrile Neutropenia: Risks Associated with Antibiotic Choice in Children with Leukemia that Undergo Transplant |
Children’s Hospital of Philadelphia / Caitlin Elgarten, MD |
Young Investigator Grants |
2018 |
Pennsylvania |
Bcl2-Family Inhibitors in Neuroblastoma: Mechanism of Action, Therapy Resistance, and Development of Biomarkers |
Children’s Hospital of Philadelphia / Claudia Zapata, MD |
Young Investigator Grants |
2019 |
Pennsylvania |
The role of overexpressed microRNA’s in the pediatric cancer rhabdomyosarcoma
|
University of Pennsylvania / Frederic Barr, MD, PhD |
Innovation Grants |
2007 |
Pennsylvania |
Alex's Lemonade Stand Foundation Center of Excellence in Childhood Cancer Drug Development and Clinical Pharmacology at The Children's Hospital of Philadelphia
|
Children’s Hospital of Philadelphia / Frank Balis, MD - Scholar: Emily Blauel, MD |
Center of Excellence Grants |
2013 |
Pennsylvania |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition
|
Children’s Hospital of Philadelphia / Yael Mossé, MD |
Reach Grants |
2013 |
Pennsylvania |
In-UTR mutations in neuroblastoma: Functional consequences and therapeutic implications |
Children’s Hospital of Philadelphia / Andrei Thomas-Tikhonenko, PhD |
Innovation Grants |
2012 |
Pennsylvania |
Modeling Juvenile Myelomonocytic Leukemia with Patient-Derived Induced Pluripotent Stem Cells |
Children’s Hospital of Philadelphia / Mitchell Weiss, M.D., Ph.D. |
Innovation Grants |
2014 |
Pennsylvania |
Developmental Therapeutics and Translational Research Program
|
Children’s Hospital of Philadelphia / John Maris |
Phase I/II Infrastructure Grants |
2005 |
Pennsylvania |